The future for vaccine development against Entamoeba histolytica
| Autor: | Joëlle St-Pierre, Kris Chadee, Jeanie Quach |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Protozoan Vaccines
Immunology Review DNA vaccination Entamoeba histolytica Immune system Antigen parasitic diseases Drug Discovery medicine Immunology and Allergy Parasite hosting Animals Humans Pharmacology Amebic colitis biology Entamoebiasis Dysentery medicine.disease biology.organism_classification Virology Vaccination Disease Models Animal |
| Zdroj: | Human vaccinesimmunotherapeutics. 10(6) |
| ISSN: | 2164-554X |
| Popis: | Entamoeba histolytica is the causative agent of amebiasis, one of the top three parasitic causes of mortality worldwide. In the majority of infected individuals, E. histolytica asymptomatically colonizes the large intestine, while in others, the parasite breaches the mucosal epithelial barrier to cause amebic colitis and can disseminate to soft organs to cause abscesses. Vaccinations using native and recombinant forms of the parasite Gal-lectin have been successful in protecting animals against intestinal amebiasis and amebic liver abscess. Protection against amebic liver abscesses has also been reported by targeting other E. histolytica components including the serine-rich protein and the 29-kDa-reductase antigen. To date, vaccines against the Gal-lectin hold the most promise but clinical trials will be required to validate its efficacy in humans. Here, we review the current strategies and future perspectives involved in the development of a vaccine against E. histolytica. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|